| 書目名稱 | Medicines and Risk/Benefit Decisions | | 編輯 | Stuart R Walker (Director of the Centre for Medici | | 視頻video | http://file.papertrans.cn/630/629507/629507.mp4 | | 叢書名稱 | CMR Workshop Series | | 圖書封面 |  | | 描述 | The third CMR Workshop prov. ided the opportunity for a group of experts from the Industry, academia and the regulatory authorities to meet and discuss ways and means by which risk benefit decisions are made during the various stages of drug development. It became apparent from the discussions that took place in October 1985, at the CIBA Foundation, that decisions are often made with limited data and inadequate methodology. The conclusions drawn from the day‘s deliberations were as follows: 1. Current methodology for assessing risk and particularly benefits must be improved; 2. Safety must be assessed in association with benefits as it is ultimately the benefit/ risk ratio which should decide the future of medicines; 3. Risks from medicines must always be viewed in relation to the risks from untreated diseases. It seemed to be the consensus of the group that such a meeting was both useful and informative and, hopefully, the publication of these proceedings will stimulate further discussion in this important area which may improve the decision-making process in drug development. The Editors wish to thank the participants for contributing to the Work- shop, together with Dr. Cyndy Lu | | 出版日期 | Book 1987 | | 關(guān)鍵詞 | care; clinical trial; diseases; medicine; perception; research | | 版次 | 1 | | doi | https://doi.org/10.1007/978-94-009-3221-0 | | isbn_softcover | 978-94-010-7946-4 | | isbn_ebook | 978-94-009-3221-0 | | copyright | MTP Press Limited 1987 |
The information of publication is updating
|
|
|Archiver|手機(jī)版|小黑屋|
派博傳思國際
( 京公網(wǎng)安備110108008328)
GMT+8, 2025-10-18 08:22
發(fā)表于 2025-3-21 17:39:54
